Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
Progression-free and overall survival is similar for minority and nonminority patients receiving CAR T-cell therapy for non-Hodgkin lymphoma.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
The approval was based on data from the phase 3 ZUMA-7 trial.
Bone marrow infiltration of lymphoma cells is a risk factor for grade 2 or higher infusion-related reactions in B-NHL treated with rituximab.
Researchers sought to determine whether the route of administration for prophylaxis would impact CNS relapse in patients with aggressive B-cell non-Hodgkin lymphomas.
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
The absolute risk for overall cancer was 4.7% during the first year of follow-up.